Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Reports Strong Q1 2024 Financial Results
Summary
Alnylam Pharmaceuticals, Inc. announced its financial results for the first quarter of 2024, reporting global net product revenues of $365 million, representing a 32% year-over-year growth. The company highlighted strong progress with its zilebesiran hypertension program and anticipates reporting topline results from the HELIOS-B Phase 3 study in late June or early July. Alnylam also reiterated its 2024 financial guidance, expecting combined net product revenues between $1,400 million and $1,500 million.
Profitelligence Alerts
Get alerts for ALNY
Be first to know when Alnylam Pharmaceuticals Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Inc. is a pioneering biotechnology company dedicated to transforming the lives of patients through RNA interference (RNAi) therapeutics. This scientific approach allows for innovative treatments that can silence genes responsible for certain diseases, offering a unique angle on genetic therapies. Alnylam's primary focus is on developing therapeutics for genetic, cardio-metabolic, hepatic infectious, and central nervous system diseases, contributing to redefining how these conditions are treated. The company's groundbreaking work in RNAi provides a platform for addressing otherwise untreatable or poorly managed medical conditions, positioning it as a leader in the biotechnology sector. With numerous collaborations, partnerships, and a growing pipeline of therapeutics, Alnylam plays a crucial role in advancing modern medicine and contributing to the evolving landscape of genetic therapeutics. Headquartered in Cambridge, Massachusetts, Alnylam underscores the critical intersection of innovation, medicine, and gene science in the financial and pharmaceutical markets.
Official SEC Documents
Advertisement